Portal de Periódicos da CAPES

Genomics of AML: Clinical Applications of Next-Generation Sequencing

2011; American Society of Hematology; Volume: 2011; Issue: 1 Linguagem: Inglês

10.1182/asheducation-2011.1.30

1520-4391

John S. Welch, Daniel C. Link,

Protein Degradation and Inhibitors

In the past decade, a series of technological advances have revolutionized our ability to interrogate cancer genomes, culminating in whole-genome sequencing, which provides genome-wide coverage at a single base-pair resolution. As sequencing technologies improve and costs decrease, it is likely that whole-genome sequencing of cancer cells will become commonplace in the diagnostic workup of patients with acute myelogenous leukemia (AML) and other cancers. The unprecedented molecular characterization provided by whole-genome sequencing offers the potential for an individualized approach to treatment in AML, bringing us one step closer to personalized medicine. In this chapter, we discuss how next-generation sequencing is being used to study cancer genomes. Recent publications of whole-genome sequencing in AML are reviewed and current limitations of whole-genome sequencing are examined, as well as current and potential future clinical applications of whole-genome sequencing.